Clinical Trial Detail

NCT ID NCT02541565
Title Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Washington
Indications

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate

Rituximab

Age Groups: adult

No variant requirements are available.